IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer

Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)

NCT04068168 ·Status: COMPLETED

A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer

NCT05380024 ·Status: UNKNOWN ·Phase: PHASE2

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

NCT03133234 ·Status: COMPLETED

A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer

NCT05492045 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study

NCT07295821 ·Status: RECRUITING ·Phase: PHASE2

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

NCT03191149 ·Status: RECRUITING ·Phase: PHASE2

A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC

NCT05991206 ·Status: RECRUITING

Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC

NCT05215951 ·Status: TERMINATED ·Phase: PHASE2

Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC

NCT00188617 ·Status: COMPLETED ·Phase: PHASE2

Study to Evaluate D-1553 in Subjects With Lung Cancer

NCT05383898 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen

NCT01850147 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

NCT05047250 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina

NCT03321695 ·Status: COMPLETED

Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer

NCT05991895 ·Status: RECRUITING

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

NCT03833154 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC

NCT05098990 ·Status: UNKNOWN ·Phase: PHASE4

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

NCT05546866 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer

NCT05127382 ·Status: UNKNOWN

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

NCT05526755 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC

NCT03684967 ·Status: WITHDRAWN ·Phase: PHASE2

Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)

NCT05085054 ·Status: UNKNOWN ·Phase: PHASE2

First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker

NCT00455936 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion

NCT05466149 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region

NCT06039683 ·Status: COMPLETED

Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)

NCT04501497 ·Status: COMPLETED